

### Technology Description



*Cryptosporidium* is an enteric parasite, with a global impact on the health, survival and economic development of more than 10 million people and animals world-wide. Approximately 2.3 million tests are performed p.a. worldwide for *Cryptosporidium* in the clinical setting, and in water testing, approximately 210,000 tests performed p.a. worldwide. Cryptogen has developed novel technologies for the rapid and precise diagnosis of human infective *Cryptosporidium* species.

### Value Proposition and Competitive Advantages

Cryptogen has developed three separate products to address the shortcomings of current *Cryptosporidium* monitoring methods used in drinking water and human diagnosis.

- *The Cryptoguard™ Environmental Viability Assay* determines *Cryptosporidium* viability through simple, novel host cell-free culture technique.
- *The Cryptoguard™ Environmental Genotyping Assay* identifies *Cryptosporidium*'s human-infectious species based on novel DNA signatures in water.
- *The Cryptoguard™ Clinical Assay* determines *Cryptosporidium* infection from faeces based on novel DNA signatures.

### Current Status/ Next Steps

Cryptogen has protected these technologies with two separate patent families (at national phase in 9 countries). Cryptogen's technologies are currently undergoing beta testing.

### Funding Requirements

Cryptogen is seeking to license its *Cryptoguard™* technologies to interested parties.

### Contact Details

Mr Cain Murphy, CEO Cryptogen Pty Ltd  
C.murphy@murdoch.edu.au  
+61 (0) 405 236 316